Lee L. Swanström (USA-France)

Jie He (China)

Michio Hongo (Japan)


OESO Website

  < back to the Program at a glance

Session 35


Monday, September 4
2:00 – 4:00 pm

Room 2



Pneumatic dilation for achalasia and other motility disorders

An evolving role and treatment paradigm


Chairs: Joel E. Richter (USA) – Eduardo de Moura (Brazil)

Discussant: Patrick S. Yachimski (USA)


  • History of pneumatic dilation for achalasia. Don O. Castell (USA)
  • Currents techniques of pneumatic dilation-fluro vs endoscopy. Patrick S. Yachimski (USA)
  • Predictive factors for good and back outcomes of pneumatic dilation in treating achalasia.
    Valter N. Felix (Brazil)
  • Randomized controlled trials of pneumatic dilation vs Botox and surgery (Heller, POEM).
    Peter Bauerfeind (Switzerland)
  • Post procedure follow-up after pneumatic dilation: role of high resolution manometry, timed barium swallow and/or FLIP. Johannes Lenglinger (Switzerland)
  • Success of pneumatic dilation in treating other motility disorders: EGJ outflow obstruction and DES, Jackhammer esophagus. Joel E. Richter (USA)
  • Efficacy of pneumatic dilation in achalasia in Chaga’s disease.
  • Complications of pneumatic dilation: Type, frequency and treatment. Radu Tutuian (Switzerland)
  • Is endoscopic dilation an adequate therapy after failure of surgical treatment? Eduardo de Moura (Brazil)
  • Why not pneumatic dilation in all patients initially with achalasia? Eduardo de Moura (Brazil)
  • Why would we ever need pneumatic dilation with treating achalasia with our new surgeries?
    Jean-Louis Frossard (Switzerland)
  • Is there a role for prolonged stent dilation compared to pneumatic dilatation? Erwin Rieder (Austria)
  • Does pneumatic dilation adversely affect subsequent treatment of achalasia with laparoscopic Heller or POEM? Lee Swanström (USA)
  • What really happens to all the patients we dilate year after year? Stephen J. Sontag (USA)





©2016 OESO – SYMPORG SA            webdesign